Patents Assigned to Spitfire Pharma LLC
  • Therapeutic Regimens and Methods for Treatment of Cardiovascular Risk Factors using a GLP-1R and GCGR Agonist
    Publication number: 20250367263
    Abstract: This disclosure relates to the once weekly dosing regimen of a dual GLP-1R and GCGR agonist, formulations, and methods of using the same for treatment of cardiovascular disease/disorder and/or reducing risk factors thereof by inducing reduction of pathogenic serum lipid mediators in a human being, wherein the human may or may not have other comorbidities such as obesity and/or type 2 diabetes. The dual GLP-1R and GCGR agonist includes the peptide product of SEQ ID NO. 1 (pemvidutide).
    Type: Application
    Filed: November 6, 2023
    Publication date: December 4, 2025
    Applicant: Spitfire Pharma LLC
    Inventors: John Joseph Suschak, III, Bertrand Victor Gilbert Georges, Sarah K. Browne, Matthew Scott Harris, M. Scot Roberts, Maynara Lucca Andrade
  • Therapeutic Regimens and Methods for Reducing Body Weight and/or Serum Lipids using a GLP-1R and GCGR Agonist
    Publication number: 20250288650
    Abstract: This disclosure relates to the once weekly dosing regimen of a dual GLP-1R and GCGR agonist, formulations, and methods of using the same for treatment of chronic weigh management and/or reducing serum lipids in a subject in need thereof with one or more co-morbidities using a pharmaceutical dosage formulation comprising a peptide product according to SEQ ID NO: 1, or peptide product that is at least 80% identical to a peptide of SEQ ID NO: 1.
    Type: Application
    Filed: March 11, 2025
    Publication date: September 18, 2025
    Applicant: Spitfire Pharma LLC
    Inventors: M. Scot Roberts, Bertrand Victor Gilbert Georges, Sarah K. Browne, Matthew Scott Harris, John Joseph Suschak, III
  • GLP-1R and GCGR Agonists, Formulations, and Methods of Use
    Publication number: 20250262280
    Abstract: This disclosure relates to the field of GLP-1R and GCGR agonists, formulations, and methods of using the same, including but not limited to dual agonist peptides of any of SEQ ID NOS. 1-10 or 12-27 conjugated to a non-ionic glycolipid surfactant.
    Type: Application
    Filed: January 22, 2025
    Publication date: August 21, 2025
    Applicant: Spitfire Pharma LLC
    Inventors: John J Nestor, Vyjayanthi Krishnan
  • Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists
    Publication number: 20250134963
    Abstract: This disclosure relates to the once weekly dosing regimen of a dual GLP-1R and GCGR agonist, formulations, and methods of using the same for treatment of chronic weight management, obesity and/or blood glucose control, including but not limited to dual agonist peptide product of SEQ ID NO. 1.
    Type: Application
    Filed: November 11, 2024
    Publication date: May 1, 2025
    Applicant: Spitfire Pharma LLC
    Inventors: Vyjayanthi Krishnan, Joyce James, Omar Roble Olhaye, Matthew Scott Harris
  • Peptide pharmaceuticals for treatment of NASH and other disorders
    Patent number: 12257229
    Abstract: The disclosure provides peptide products comprising a peptide covalently attached to a surfactant moiety which have improved properties, including increased duration of action and bioavailability. The peptide products are useful for treating insulin resistance, diabetes, obesity, metabolic syndrome and cardiovascular diseases, and conditions associated therewith, such as NASH and PCOS.
    Type: Grant
    Filed: December 20, 2022
    Date of Patent: March 25, 2025
    Assignee: Spitfire Pharma LLC
    Inventor: John J Nestor
  • Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists
    Patent number: 12171806
    Abstract: This disclosure relates to the once weekly dosing regimen of a dual GLP-1R and GCGR agonist, formulations, and methods of using the same for treatment of chronic weight management, obesity and/or blood glucose control, including but not limited to dual agonist peptide product of SEQ ID NO. 1.
    Type: Grant
    Filed: December 7, 2021
    Date of Patent: December 24, 2024
    Assignee: Spitfire Pharma LLC
    Inventors: Vyjayanthi Krishnan, Joyce James, Omar Roble Olhaye, Matthew Scott Harris
  • Therapeutic Regimens and Methods for Treatment of Cardiovascular Risk Factors using a GLP-1R and GCGR Agonist
    Publication number: 20240277815
    Abstract: This disclosure relates to the once weekly dosing regimen of a dual GLP-1R and GCGR agonist, formulations, and methods of using the same for treatment of cardiovascular disease/disorder and/or reducing risk factors thereof by inducing reduction of pathogenic serum lipid mediators in a human being, wherein the human may or may not have other comorbidities such as obesity and/or type 2 diabetes. The dual GLP-1R and GCGR agonist includes the peptide product of SEQ ID NO. 1 (pemvidutide).
    Type: Application
    Filed: November 6, 2023
    Publication date: August 22, 2024
    Applicant: Spitfire Pharma LLC
    Inventors: John Joseph Suschak, III, Bertrand Victor Gilbert Georges, Sarah K. Browne, Matthew Scott Harris, M. Scot Roberts, Maynara Lucca Andrade
  • Therapeutic Regimens and Methods for Reducing Body Weight in a Subject with Fatty Liver Disease using a GLP-1R and GCGR Agonist
    Publication number: 20240269238
    Abstract: This disclosure relates to the once weekly dosing regimen of a dual GLP-1R and GCGR agonist, formulations, and methods of using the same for inducing weight loss in a human being with fatty liver disease, wherein the human may or may not have other comorbidities such as type 2 diabetes and/or cardiovascular disease/disorder. The dual GLP-1R and GCGR agonist includes the peptide product of SEQ ID NO. 1 (pemvidutide).
    Type: Application
    Filed: September 14, 2023
    Publication date: August 15, 2024
    Applicant: Spitfire Pharma LLC
    Inventors: Sarah K. Browne, Matthew Scott Harris, John Joseph Suschak, III, Bertrand Victor Gilbert Georges, M. Scot Roberts
  • Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists
    Publication number: 20230104501
    Abstract: This disclosure relates to the once weekly dosing regimen of a dual GLP-1R and GCGR agonist, formulations, and methods of using the same for treatment of chronic weight management, obesity and/or blood glucose control, including but not limited to dual agonist peptide product of SEQ ID NO. 1.
    Type: Application
    Filed: December 7, 2021
    Publication date: April 6, 2023
    Applicant: Spitfire Pharma LLC
    Inventors: Vyjayanthi Krishnan, Joyce James, Omar Roble Olhaye, Matthew Scott Harris
  • GLP-1R and GCGR Agonists, Formulations, and Methods of Use
    Publication number: 20210290732
    Abstract: This disclosure relates to the field of GLP-1R and GCGR agonists, formulations, and methods of using the same, including but not limited to dual agonist peptides of any of SEQ ID NOS. 1-10 or 12-27 conjugated to a non-ionic glycolipid surfactant.
    Type: Application
    Filed: February 21, 2021
    Publication date: September 23, 2021
    Applicant: Spitfire Pharma LLC
    Inventors: John J Nestor, Vyjayanthi Krishnan